The Lancet Neurology
Fecha de publicación: Mayo de 2021
Autores: Prof Eduardo Tolosa, PhD †, Alicia Garrido, MD, Sonja W Scholz, MD, Prof Werner Poewe, PhD †
DOI: https://doi.org/10.1016/S1474-4422(21)00030-2
Background: Parkinson’s disease is the second most common neurodegenerative disease and its prevalence has been projected to double over the next 30 years. An accurate diagnosis of Parkinson’s disease remains challenging and the characterisation of the earliest stages of the disease is ongoing. Recent developments over the past 5 years include the validation of clinical diagnostic criteria, the introduction and testing of research criteria for prodromal Parkinson’s disease, and the identification of genetic subtypes and a growing number of genetic variants associated with risk of Parkinson’s disease.
